• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Identification of tumor microenvironment involving tumor infiltrating regulatory T cells in lung cancer

Research Project

Project/Area Number 16K21533
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Tumor therapeutics
Tumor biology
Research InstitutionKawasaki Medical School

Principal Investigator

Kurose Koji  川崎医科大学, 医学部, 助教 (30551139)

Research Collaborator Ohue Yoshihiro  川崎医科大学, 医学部, 講師 (70435014)
Nakayama Eiichi  川崎医科大学, 客員教授 (60180428)
Oka Mikio  川崎医科大学, 医学部, 教授 (40223995)
Project Period (FY) 2016-04-01 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Keywords肺癌微小環境 / 制御性T細胞 / Treg / PD-L1 / PD-1 / TIM-3 / 腫瘍浸潤リンパ球 / 非小細胞肺癌 / 肺がん
Outline of Final Research Achievements

In this study, in order to clarify the presence or absence of inflammation of the tumor microenvironment and the involvement of tumor infiltrating regulatory T cells (Treg) in lung cancer, we examined the association of tumor infiltrating lymphocytes, Treg fraction, and inhibitory molecules PD-1, TIM-3 on T-cells with PD-L1 on tumor cells. In the high expression group of PD-L1, there were many tumor infiltrating lymphocytes, whereas there were also many activated Tregs, and high expression of PD-1 and TIM-3 on T cells was observed. Furthermore, Treg depletion using anti-CCR4 antibody resulted in an increase in the number of tumor infiltrating lymphocytes and an increase in the expression of PD-L1 on tumor cells. In the high expression group of PD-L1, Treg depletion and anti-PD-1 therapy may enhance the therapeutic effect.

Report

(3 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Research-status Report
  • Research Products

    (7 results)

All 2018 2017 2016

All Journal Article (3 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 3 results,  Open Access: 1 results,  Acknowledgement Compliant: 2 results) Presentation (4 results) (of which Int'l Joint Research: 2 results)

  • [Journal Article] NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC2017

    • Author(s)
      Takeoka T, Nagase H, Kurose K, Ohue Y, Yamasaki M, Takiguchi S, Sato E, Isobe M, Kanazawa T, Matsumoto M, Iwahori K, Kawashima A, Morimoto-Okazawa A, Nishikawa H, Oka M, Pan L, Venhaus R, Nakayama E, Mori M, Doki Y, Wada H.
    • Journal Title

      J Immunother

      Volume: epub Issue: 4 Pages: 140-147

    • DOI

      10.1097/cji.0000000000000162

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
  • [Journal Article] Nivolumab-induced polyarthritis.2017

    • Author(s)
      Kodama S, Kurose K, Mukai T, Morita Y.
    • Journal Title

      BMJ Case Rep.

      Volume: - Pages: bcr-2017-223387

    • DOI

      10.1136/bcr-2017-223387

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells.2016

    • Author(s)
      Ohue Y, Kurose K, Nozawa R, Isobe M, Nishio Y, Tanaka T, Doki Y, Hori T, Fukuoka J, Oka M, Nakayama E
    • Journal Title

      Cancer Immunology Research

      Volume: 4 Pages: 1049-1060

    • Related Report
      2016 Research-status Report
    • Peer Reviewed / Acknowledgement Compliant
  • [Presentation] Reviving chemotherapy sensitivity after anti-CCR4 mAb (mogamulizumab) treatment in lung cancer patients2018

    • Author(s)
      黒瀬 浩史, 大植 祥弘, 磯辺 みどり, 鈴木 進, 和田 尚, 上田 龍三, 中山 睿一, 岡 三喜男
    • Organizer
      第15回日本免疫治療学研究会学術集会
    • Related Report
      2017 Annual Research Report
  • [Presentation] Reviving chemotherapy sensitivity after anti-CCR4 mAb (mogamulizumab) treatment in lung cancer patients2017

    • Author(s)
      Kurose K, Ohue Y, Isobe M, Suzuki S, Wada H, Oka M, Ueda R, Nakayama E.
    • Organizer
      Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Reviving chemotherapy sensitivity after anti-CCR4 mAb (mogamulizumab) treatment in lung cancer patients2017

    • Author(s)
      Koji Kurose, Yoshihiro Ohue, Midori Isobe, Susumu Suzuki, Hisashi Wada, Ryuzo Ueda, Eiichi Nakayama and Mikio Oka
    • Organizer
      IASLC 18th world conference on lung cancer(WCLC 2017)
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research
  • [Presentation] 肺腺癌のTIM-3/Galectin-9経路を介した免疫抑制と予後2016

    • Author(s)
      黒瀬 浩史
    • Organizer
      第57回日本肺癌学会学術集会
    • Place of Presentation
      福岡国際会議場(福岡県福岡市)
    • Related Report
      2016 Research-status Report

URL: 

Published: 2016-04-21   Modified: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi